DPP4 and diabetes mellitus: Dipeptidyl peptidase-4 (DPP4) deactivates incretin hormones, whereas DPP4 inhibitors, such as sitagliptin, block this degradation, increase the incretin levels, and prolong insulin secretion [7]; therefore, sitagliptin could be a potential therapeutic for type 2 diabetes mellitus.